Halozyme Therapeutics, Inc. (FRA:RV7)
Germany · Delayed Price · Currency is EUR 59.66
+0.66 (1.12%)
At close: Jan 27, 2026
Halozyme Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 595.49 | 444.09 | 281.59 | 202.13 | 402.71 | 129.09 |
Depreciation & Amortization | 81.79 | 81.31 | 82.36 | 49.64 | 3 | 3.28 |
Other Amortization | 7.4 | 7.35 | 7.3 | 7.84 | 3.64 | 14.14 |
Loss (Gain) From Sale of Assets | -0.15 | 1.53 | 0.61 | 0.13 | - | -0.77 |
Asset Writedown & Restructuring Costs | - | - | 2.5 | - | - | 0.58 |
Loss (Gain) From Sale of Investments | -5.53 | -10.93 | -6.32 | 2.83 | 2.26 | 0.84 |
Stock-Based Compensation | 46.46 | 43.39 | 36.62 | 24.4 | 20.82 | 17.2 |
Other Operating Activities | 2.99 | 1.6 | 22.58 | 39.09 | -136.72 | -0.53 |
Change in Accounts Receivable | -60.29 | -74.25 | -3.34 | -83.94 | 6.76 | -38.29 |
Change in Inventory | -23.95 | -67.38 | -26.88 | -17.48 | 7.37 | -31.39 |
Change in Accounts Payable | 22.55 | 46.99 | -12.55 | 24.54 | 1.17 | -41.21 |
Change in Other Net Operating Assets | -55.76 | 5.36 | 4.1 | -9.06 | -11.56 | 2.52 |
Operating Cash Flow | 611 | 479.06 | 388.57 | 240.11 | 299.44 | 55.45 |
Operating Cash Flow Growth | 51.63% | 23.29% | 61.83% | -19.81% | 439.98% | - |
Capital Expenditures | -8.6 | -10.7 | -15.29 | -4.81 | -1.46 | -2.5 |
Sale of Property, Plant & Equipment | - | - | - | 26.01 | - | 1.08 |
Cash Acquisitions | - | - | - | -999.12 | - | - |
Investment in Securities | 234.05 | -252.03 | -81.62 | 490.92 | -404.83 | 79.78 |
Investing Cash Flow | 225.46 | -262.72 | -96.91 | -487.01 | -406.29 | 78.35 |
Short-Term Debt Issued | - | - | - | 370 | - | - |
Long-Term Debt Issued | - | - | - | 702 | 784.88 | - |
Total Debt Issued | - | - | - | 1,072 | 784.88 | - |
Short-Term Debt Repaid | - | - | - | -370 | - | - |
Long-Term Debt Repaid | - | - | -13.48 | -77.45 | -369.06 | -19.56 |
Total Debt Repaid | - | - | -13.48 | -447.45 | -369.06 | -19.56 |
Net Debt Issued (Repaid) | - | - | -13.48 | 624.55 | 415.81 | -19.56 |
Issuance of Common Stock | 21.27 | 31.14 | 7.88 | 14.05 | 12.54 | 63.39 |
Repurchase of Common Stock | -592.37 | -250 | -402.38 | -200 | -350.06 | -150.12 |
Other Financing Activities | - | - | - | -76.22 | -0.42 | - |
Financing Cash Flow | -571.1 | -218.86 | -407.99 | 362.37 | 77.87 | -106.28 |
Net Cash Flow | 265.35 | -2.52 | -116.33 | 115.48 | -28.98 | 27.52 |
Free Cash Flow | 602.4 | 468.37 | 373.28 | 235.3 | 297.98 | 52.95 |
Free Cash Flow Growth | 53.40% | 25.47% | 58.64% | -21.04% | 462.76% | - |
Free Cash Flow Margin | 48.47% | 46.13% | 45.01% | 35.64% | 67.22% | 19.79% |
Free Cash Flow Per Share | 4.80 | 3.62 | 2.78 | 1.67 | 2.03 | 0.37 |
Cash Interest Paid | 10.57 | 10.57 | 11.41 | 6.11 | 3.3 | 6.53 |
Cash Income Tax Paid | 80.62 | 80.62 | 31.76 | 16.22 | -0.38 | 0.18 |
Levered Free Cash Flow | 428.44 | 395.43 | 274.74 | 146.42 | 197.82 | 3.92 |
Unlevered Free Cash Flow | 432.13 | 399.38 | 279.16 | 149.17 | 198.88 | 2.52 |
Change in Working Capital | -117.46 | -89.28 | -38.67 | -85.95 | 3.74 | -108.37 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.